The remaining workforce, led by senior medical adviser David Hough, MD, will focus on clinical development and FDA engagement, according to an Aug. 15 news release from Lykos.
Dr. Hough previously served as vice president of research and development at Johnson & Johnson Innovative Medicine.
As part of the reorganization, Rick Doblin, PhD, will step down from Lykos’ board of directors. Dr. Doblin is the founder and president of the nonprofit behind Lykos, Multidisciplinary Association for Psychedelic Studies.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
